United States - English - NLM (National Library of Medicine)

akorn - loteprednol etabonate (unii: yeh1ez96k6) (loteprednol - unii:z8cbu6kr16) - loteprednol etabonate ophthalmic gel is a corticosteroid indicated for the treatment of post-operative inflammation and pain following ocular surgery. loteprednol etabonate ophthalmic gel is contraindicated in most viral diseases of the cornea and conjunctiva including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella, in mycobacterial infection of the eye and fungal diseases of ocular structures. risk summary there are no adequate and well-controlled studies with loteprednol etabonate in pregnant women. loteprednol etabonate produced teratogenicity at clinically relevant doses in the rabbit and rat when administered orally during pregnancy. loteprednol etabonate produced malformations when administered orally to pregnant rabbits at doses ≥ 1.2 times the recommended human ophthalmic dose (rhod) and to pregnant rats at doses ≥ 30 times the rhod. in pregnant rats receiving oral doses of loteprednol etabonate during the period equivalent to the last trimester of pregnancy through

United States - English - NLM (National Library of Medicine)

bausch & lomb incorporated - loteprednol etabonate (unii: yeh1ez96k6) (loteprednol - unii:z8cbu6kr16) - loteprednol etabonate ophthalmic gel is a corticosteroid indicated for the treatment of post-operative inflammation and pain following ocular surgery. loteprednol etabonate ophthalmic gel is contraindicated in most viral diseases of the cornea and conjunctiva including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella, in mycobacterial infection of the eye and fungal diseases of ocular structures. risk summary there are no adequate and well-controlled studies with loteprednol etabonate in pregnant women. loteprednol etabonate produced teratogenicity at clinically relevant doses in the rabbit and rat when administered orally during pregnancy. loteprednol etabonate produced malformations when administered orally to pregnant rabbits at doses ≥ 1.2 times the recommended human ophthalmic dose (rhod) and to pregnant rats at doses ≥ 30 times the rhod. in pregnant rats receiving oral doses of loteprednol etabonate during the period equivalent to the last trimester of pregnancy through

United States - English - NLM (National Library of Medicine)

bausch & lomb americas inc. - loteprednol etabonate (unii: yeh1ez96k6) (loteprednol - unii:z8cbu6kr16) - loteprednol etabonate ophthalmic gel is a corticosteroid indicated for the treatment of post-operative inflammation and pain following ocular surgery. loteprednol etabonate ophthalmic gel is contraindicated in most viral diseases of the cornea and conjunctiva including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella, in mycobacterial infection of the eye and fungal diseases of ocular structures. risk summary there are no adequate and well-controlled studies with loteprednol etabonate in pregnant women. loteprednol etabonate produced teratogenicity at clinically relevant doses in the rabbit and rat when administered orally during pregnancy. loteprednol etabonate produced malformations when administered orally to pregnant rabbits at doses ≥ 1.2 times the recommended human ophthalmic dose (rhod) and to pregnant rats at doses ≥ 30 times the rhod. in pregnant rats receiving oral doses of loteprednol etabonate during the period equivalent to the last trimester of pregnancy through

United States - English - NLM (National Library of Medicine)

akorn - loteprednol etabonate (unii: yeh1ez96k6) (loteprednol - unii:z8cbu6kr16) - loteprednol etabonate is indicated for the treatment of steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides, when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation. loteprednol etabonate is less effective than prednisolone acetate 1% in two 28-day controlled clinical studies in acute anterior uveitis, where 72% of patients treated with loteprednol etabonate experienced resolution of anterior chamber cells, compared to 87% of patients treated with prednisolone acetate 1%. the incidence of patients with clinically significant increases in iop (≥10 mmhg) was 1% with loteprednol etabonate and 6% with prednisolone acetate 1%. loteprednol etabonate should not be used in patients who require a more potent corticosteroid for this indi

United States - English - NLM (National Library of Medicine)

oceanside pharmaceuticals - loteprednol etabonate (unii: yeh1ez96k6) (loteprednol - unii:z8cbu6kr16) - loteprednol etabonate ophthalmic suspension is indicated for the treatment of steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides, when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation. loteprednol etabonate is less effective than prednisolone acetate 1% in two 28-day controlled clinical studies in acute anterior uveitis, where 72% of patients treated with loteprednol etabonate experienced resolution of anterior chamber cells, compared to 87% of patients treated with prednisolone acetate 1%. the incidence of patients with clinically significant increases in iop (≥10 mmhg) was 1% with loteprednol etabonate and 6% with prednisolone acetate 1%. loteprednol etabonate should not be used in patients who require a more potent cortic

United States - English - NLM (National Library of Medicine)

bausch & lomb americas inc. - loteprednol etabonate (unii: yeh1ez96k6) (loteprednol - unii:z8cbu6kr16) - loteprednol etabonate ophthalmic suspension is indicated for the treatment of steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides, when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation. loteprednol etabonate is less effective than prednisolone acetate 1% in two 28-day controlled clinical studies in acute anterior uveitis, where 72% of patients treated with loteprednol etabonate experienced resolution of anterior chamber cells, compared to 87% of patients treated with prednisolone acetate 1%. the incidence of patients with clinically significant increases in iop (≥10 mmhg) was 1% with loteprednol etabonate and 6% with prednisolone acetate 1%. loteprednol etabonate should not be used in patients who require a more potent cortic

United States - English - NLM (National Library of Medicine)

sun pharmaceutical industries, inc. - loteprednol etabonate (unii: yeh1ez96k6) (loteprednol - unii:z8cbu6kr16) - loteprednol etabonate ophthalmic suspension is indicated for the treatment of steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides, when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation. loteprednol etabonate ophthalmic suspension is less effective than prednisolone acetate 1% in two 28-day controlled clinical studies in acute anterior uveitis, where 72% of patients treated with loteprednol etabonate ophthalmic suspension experienced resolution of anterior chamber cells, compared to 87% of patients treated with prednisolone acetate 1%. the incidence of patients with clinically significant increases in iop (≥10 mmhg) was 1% with loteprednol etabonate ophthalmic suspension and 6% with prednisolone acetate 1%. loteprednol etabona

United States - English - NLM (National Library of Medicine)

bausch & lomb incorporated - loteprednol etabonate (unii: yeh1ez96k6) (loteprednol - unii:z8cbu6kr16) - loteprednol etabonate 5 mg in 1 g - lotemax® (loteprednol etabonate ophthalmic gel) 0.5% is a corticosteroid indicated for the treatment of post-operative inflammation and pain following ocular surgery. lotemax is contraindicated in most viral diseases of the cornea and conjunctiva including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella, in mycobacterial infection of the eye and fungal diseases of ocular structures. risk summary there are no adequate and well-controlled studies with loteprednol etabonate in pregnant women. loteprednol etabonate produced teratogenicity at clinically relevant doses in the rabbit and rat when administered orally during pregnancy. loteprednol etabonate produced malformations when administered orally to pregnant rabbits at doses ≥1.2 times the recommended human ophthalmic dose (rhod) and to pregnant rats at doses ≥ 30 times the rhod. in pregnant rats receiving oral doses of loteprednol etabonate during the period equivalent to the last trimester of pregnancy through lactation in

United States - English - NLM (National Library of Medicine)

bausch & lomb incorporated - loteprednol etabonate (unii: yeh1ez96k6) (loteprednol - unii:z8cbu6kr16) - loteprednol etabonate 5 mg in 1 g - lotemax® (loteprednol etabonate ophthalmic ointment) 0.5% ointment is a corticosteroid indicated for the treatment of post-operative inflammation and pain following ocular surgery. lotemax ointment, as with other ophthalmic corticosteroids, is contraindicated in most viral diseases of the cornea and conjunctiva including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella, and also in mycobacterial infection of the eye and fungal diseases of ocular structures. risk summary there are no adequate and well-controlled studies with loteprednol etabonate in pregnant women. loteprednol etabonate produced teratogenicity at clinically relevant doses in the rabbit and rat when administered orally during pregnancy. loteprednol etabonate produced malformations when administered orally to pregnant rabbits at doses ≥ 1.6 times the recommended human ophthalmic dose (rhod) and to pregnant rats at doses ≥ 41 times the rhod. in pregnant rats receiving oral doses of loteprednol etabonate during t

United States - English - NLM (National Library of Medicine)

bausch & lomb incorporated - loteprednol etabonate (unii: yeh1ez96k6) (loteprednol - unii:z8cbu6kr16), tobramycin (unii: vz8rrz51vk) (tobramycin - unii:vz8rrz51vk) - loteprednol etabonate 5 mg in 1 ml - zylet® (loteprednol etabonate and tobramycin ophthalmic suspension), 0.5%/0.3% is a topical anti-infective and corticosteroid combination for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of bacterial ocular infection exists. ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, and where the inherent risk of steroid use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation. they are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns, or penetration of foreign bodies. the use of a combination drug with an anti-infective component is indicated where the risk of superficial ocular infection is high or where th